| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | EVP, Chief Financial Officer
3 companies
Daniel K Spiegelman is EVP, Chief Financial Officer at BMRN, with reported holdings spanning 3 companies. Daniel K Spiegelman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.9M at current prices.
Our model assigns Daniel K Spiegelman a middling insider score of 59/100, based on 6 past trades. Over a 12-month horizon, 83.3% of those trades were profitable, with an average 12-month return of +33.7%.
Daniel K Spiegelman's largest disclosed position is in BMRN as EVP, Chief Financial Officer, worth about $2.7M. The BMRN filings lean toward selling, a net 125,414 shares.
Daniel K Spiegelman has 52 Form 4 filings on record from May 2016 to June 2026, across 6 companies: Director at vTv Therapeutics (VTVT), 2024–2026; Director at Maze Therapeutics (MAZE), 2025–2026; Director at Spruce Biosciences (SPRB), 2021–2026, and 3 more.
The 75 reported transactions were 21 open-market sales, 18 option or other derivative awards, 17 stock awards and 13 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 17 sales worth about $12.3M.
The largest open-market sale was 35,000 shares of BMRN at an average $94.07 on March 1, 2017, about $3.3M.
1 of the 2 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2024 | MYGN Myriad Genetics Inc | Director | Sell10b5-1 | 7,576 | $22.04 | $167,012.92 | -18.7% | +22.9% | -76.3% | |
| Jun 2, 2023 | MYGN Myriad Genetics Inc | Director | Sell | 8,638 | $23.01 | $198,760.38 | -17.6% | -23.8% | -2.9% | |
| Jun 6, 2022 | MYGN Myriad Genetics Inc | Director | Sell | 6,424 | $19.25 | $123,672.92 | -15.9% | +14.0% | +20.5% | |
| Jun 17, 2021 | MYGN Myriad Genetics Inc | Director | Sell | 3,139 | $30.52 | $95,794.75 | -11.9% | +6.7% | -46.0% | |
| May 28, 2021 | MYGN Myriad Genetics Inc | Director | Sell | 7,142 | $28.99 | $207,023.01 | -34.7% | +17.1% | -19.3% | |
| Apr 1, 2019 | BMRN Biomarin Pharmaceutical Inc | EVP, Chief Financial Officer | Sell | 13,473 | $89.00 | $1,199,097.00 | -22.1% | - | - | |
| Mar 27, 2019 | BMRN Biomarin Pharmaceutical Inc | EVP, Chief Financial Officer | Sell | 100 | $90.00 | $9,000.00 | -0.2% | - | - | |
| Jun 22, 2018 | BMRN Biomarin Pharmaceutical Inc | EVP, Chief Financial Officer | Sell | 10,000 | $99.00 | $990,004.72 | -16.4% | - | - | |
| Apr 23, 2018 | BMRN Biomarin Pharmaceutical Inc | EVP, Chief Financial Officer | Sell | 11,059 | $82.15 | $908,496.85 | -15.0% | - | - | |
| Mar 16, 2017 | BMRN Biomarin Pharmaceutical Inc | EVP, Chief Financial Officer | Sell | 1,989 | $91.96 | $182,908.44 | -12.1% | - | - |